Sudden Natural Deaths: Cardiac, SIDS, Anaphylaxis

Sudden Infant Death Syndrome (SIDS) and the broader category Sudden Unexpected Death in Infancy (SUDI) are not diagnoses; they are investigation frameworks and, in the case of SIDS, a diagnosis of exclusion. The American Academy of Pediatrics (AAP) defines SIDS as the sudden unexpected death of an infant less than one year of age, with onset of a fatal episode apparently occurring during sleep, that remains unexplained after a thorough case investigation including a complete autopsy, death-scene investigation, and review of the clinical history. The UK uses SUDI as the broader umbrella term, with SIDS as one sub-category alongside explained causes of sudden infant death and the unresolved cases.

The AAP's Back to Sleep (now Safe to Sleep) public campaign, launched in 1994 and expanded internationally, reduced SIDS rates in the United States by approximately 50 percent between 1992 and 1996 by promoting supine sleep position. The same campaign was replicated in the UK (Foundation for the Study of Infant Deaths, FSID, now The Lullaby Trust), New Zealand (the country with one of the highest SIDS rates before the campaign), Germany, and Australia. India does not have a nationally equivalent public-health campaign, but AIIMS Delhi and the Indian Academy of Pediatrics have issued safe-sleep guidance aligned broadly with AAP recommendations. Despite these reductions, SIDS remains the leading cause of post-neonatal infant death in most high-income countries.

The medico-legal importance of SIDS as a diagnosis of exclusion is threefold. First, an autopsy finding of pulmonary congestion, petechial haemorrhages on the pleural and thymic surfaces, and minor thymic petechiae is the expected finding in a SIDS death and does not indicate mechanical asphyxia. In the Sally Clark case (1999 UK), paediatrician Roy Meadow testified not only that two SIDS deaths in one family had a probability of 1 in 73 million (a statistical error that compounded a baseline error in population data) but also that the petechiae found at post-mortem were inconsistent with SIDS. Subsequent review found they were entirely consistent with SIDS and inconsistent with mechanical asphyxia. Clark's convictions were quashed in 2003. Trupti Patel was acquitted in 2003 on similar grounds after defence experts challenged the same reasoning. The Cannings case led to a Crown Prosecution Service review of all convictions in similar circumstances.

Second, SIDS has a recognised genetic overlap with LQTS and other channelopathies. Approximately 10 to 20 percent of SIDS cases in gene-panel studies harbour rare variants in ion-channel genes, particularly SCN5A and KCNQ1. This means that the SIDS investigation is now considered incomplete in many jurisdictions without post-mortem genetic testing, because family members may carry the same variant and require clinical monitoring and cascade screening.

Third, the socioeconomic and racial disparities in SIDS rates are medico-legally significant in that they affect the prior probability a pathologist applies to the differential between SIDS and non-accidental injury. In both the US and UK, SIDS rates are substantially higher in lower-income families and in indigenous populations, and the literature on implicit bias in sudden infant death investigation documents that infants from higher-income families are less likely to be subjected to skeletal survey or ophthalmology consultation even when the death-scene investigation points to unresolved questions.

Anaphylaxis deaths at autopsy present a persistent challenge: the pathological findings are non-specific, rapidly reversible post-mortem, and often minimal. The classic anaphylaxis death shows laryngeal oedema, pulmonary hyperinflation with air trapping, visceral congestion, and urticaria or angioedema of the skin, but none of these findings is invariably present, and all can be absent in a death that was unquestionably anaphylactic. The diagnosis in a suspected case depends on combining the autopsy findings with the post-mortem tryptase level, the clinical history, and the exposure history.

Serum tryptase, released from mast cells during degranulation, is the most reliable post-mortem biochemical marker for anaphylaxis. In an anaphylactic death, tryptase levels in post-mortem blood (preferably drawn from a peripheral site within hours of death, as central venous samples suffer from post-mortem redistribution from mast-cell-rich periaortic tissue) are elevated above the clinical threshold of 11.4 nanograms per millilitre used by the UK Medicines and Healthcare products Regulatory Agency (MHRA) in its guidance on anaphylaxis death investigation. The British Society for Allergy and Clinical Immunology (BSACI) and the Royal College of Pathologists (RCPath) jointly issued updated guidance in 2017 recommending tryptase sampling within 6 hours of death as standard practice. In the United States, the College of American Pathologists and the American Academy of Forensic Sciences (AAFS) have incorporated tryptase into their sudden death investigation protocols. In India, the AIIMS Delhi standard operating procedure for sudden death autopsy includes a tryptase draw where the clinical history suggests an allergic reaction, though no national protocol mandating this has been issued.

Food-related anaphylaxis deaths are predominantly caused by peanut, tree nut, sesame, fish, shellfish, and dairy in high-income countries. The Natasha Ednan-Laperouse case (UK, 2016) in which a 15-year-old died of sesame-seed anaphylaxis from a Pret a Manger baguette that carried no allergen labelling led to Natasha's Law (Food Information Amendment Regulations 2021), which requires mandatory full-ingredient labelling on pre-packed-for-direct-sale food in the UK. A parallel regulatory trajectory is occurring in the US under FDA Food Safety Modernization Act allergen labelling provisions. The forensic pathologist in a food anaphylaxis death must preserve gastric contents for allergen analysis and retrieve purchasing and dietary history for the pre-death period.

Drug-induced anaphylaxis in clinical settings is most commonly caused by penicillin and related beta-lactam antibiotics, aspirin and NSAIDs, neuromuscular blocking agents (particularly in the perioperative context), and radiographic contrast media. In a drug-induced anaphylaxis death in a medical setting, the differential between anaphylaxis and an adverse drug event without an IgE-mediated mechanism is relevant to whether the death attracts negligence liability. The MHRA Yellow Card scheme in the UK and the FDA MedWatch programme in the US are the reporting channels. In India, the Pharmacovigilance Programme of India (PvPI), operated by AIIMS Delhi, handles adverse drug event reporting.

Insect-venom anaphylaxis, predominantly from Hymenoptera (honeybee, wasp, hornet), is the second most common cause of anaphylaxis death in community settings in Europe and North America. The UK Resuscitation Council guidelines and the European Academy of Allergy and Clinical Immunology (EAACI) guidelines both recommend adrenaline autoinjector prescription (EpiPen, Emerade, Jext) for patients with a previous systemic reaction to insect venom.

Fatal asthma accounts for approximately 1,200 deaths annually in the UK (NHS England data), over 3,500 in the US (CDC vital statistics), and a substantial but systematically under-counted number in India where diagnostic coding of asthma-related deaths in community settings is unreliable. The autopsy in a status asthmaticus death shows characteristic findings: lungs that fail to collapse on removal (pulmonary hyperinflation from air trapping), a dry-cut surface with thick mucus plugs in medium-sized bronchi, a pink colour compared to the red congestion of pneumonia, and histologically, goblet cell hyperplasia, thickened basement membrane, smooth-muscle hypertrophy, and eosinophilic airway infiltration. Charcot-Leyden crystals derived from eosinophil breakdown may be visible in the mucus.

The medico-legal question in a fatal asthma death is whether the death was precipitated by a failure in the standard of care. In the UK, the National Review of Asthma Deaths (NRAD, 2014) found that approximately two-thirds of deaths from asthma were avoidable, most commonly because of under-prescription of inhaled corticosteroids, failure to prescribe reliever inhalers, and inadequate monitoring. In the US, the National Asthma Education and Prevention Program (NAEPP) stepwise management guidelines define the standard of care. In India, the Global Initiative for Asthma (GINA) guidelines are the operative reference standard, though adherence in primary care settings is variable.

Ruptured cerebral aneurysm, predominantly affecting the circle of Willis at the bifurcation of the middle cerebral artery, the junction of the anterior communicating artery, or the basilar tip, accounts for roughly 5 percent of all strokes globally and presents to the forensic pathologist as a sudden-onset death with no prodrome in a person who may have had no known diagnosis. The clinical history, when it can be reconstructed, frequently includes a severe sudden headache described as "the worst of my life" in the minutes before collapse, but this information is often unavailable to the medico-legal officer when the death is unwitnessed.

At autopsy, the brain in a subarachnoid haemorrhage from ruptured aneurysm shows blood in the basal cisterns (particularly the chiasmatic and interpeduncular cisterns), tracking into the Sylvian fissures and over the cerebral convexities. The aneurysmal sac, if intact enough to be found, is typically a thin-walled berry-shaped outpouching at an arterial bifurcation. The forensic pathologist must distinguish subarachnoid haemorrhage secondary to traumatic rupture (where there is usually evidence of a blow to the head, a contre-coup injury pattern, or an extradural component) from spontaneous aneurysmal rupture.

Ruptured aortic aneurysm, most commonly an abdominal aortic aneurysm (AAA) in men over 65 with hypertension and tobacco use history, presents as a massive haemoperitoneum or retroperitoneal haematoma. The AAA diameter threshold at which elective surgical repair is typically recommended (5.5 cm in most UK and US guidelines, 5.0 cm for women under European Society of Vascular Surgery guidelines) is relevant if the medico-legal question is whether missed screening or delayed treatment contributed to the rupture.

Classifying a death as natural in manner does not close every downstream question. Three distinct tracks often open at the point the manner determination is made.

The first is the negligence track. A ruptured AAA in a patient whose aneurysm was known and whose surgical referral was delayed, a fatal asthma death in a patient whose GP had failed to prescribe a preventer inhaler, an anaphylaxis death in a patient who was discharged from an emergency department without adrenaline autoinjector provision: each is a natural death in the sense that the immediate cause was a biological process, but each may also be a case of medical negligence. The interface between natural-manner certification and negligence liability is explored in detail in the medical negligence module. The forensic pathologist's role is to accurately characterise the cause and mechanism of death; the negligence determination is a legal question that follows from, but does not alter, the autopsy findings.

The second is the genetic-cascade track. HCM, ARVC, LQTS, Brugada syndrome, and CPVT are all dominantly inherited conditions with first-degree relatives at 50 percent risk. A sudden death in a young person from an inherited cardiac condition is, by definition, a family health matter. In the UK, RCPath guidelines and NICE CG96 (familial hypercholesterolaemia guidance as a template) call for post-mortem genetic testing and communication of results to the family's GP for cascade screening. In the US, the Heart Rhythm Society and American College of Cardiology have issued similar guidance. In India, the National Health Policy's move toward universal screening for NCDs creates a framework, but specific sudden-death genetic cascade protocols are not yet formalised.

The third is the public-health track. SIDS safe-sleep interventions, allergen-labelling legislation, adrenaline autoinjector prescribing policy, asthma preventive care: each of these is a public-health response to a pattern of natural deaths, and that pattern depends on accurate cause-of-death coding in the first instance. Inaccurate or vague cause-of-death certification ("cardiac arrest", "respiratory failure") without specifying the underlying condition deprives the vital-statistics system of the data it needs to identify preventable clusters.